A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results

Samer A. Srour, Shaoying Li, Uday R. Popat, Muzaffar H. Qazilbash, Sara Lozano-Cerrada, Farzeneh Maadani, Amin Alousi, Partow Kebriaei, Paolo Anderlini, Yago Nieto, Roy Jones, Elizabeth Shpall, Richard E. Champlin, Chitra Hosing

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Fingerprint

Dive into the research topics of 'A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results'. Together they form a unique fingerprint.

Medicine & Life Sciences